BioCentury | May 28, 2020
Distillery Therapeutics

microRNA cluster identified as targets for ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Targeting the miR-15a/miR-16-1 cluster to enhance blood-brain barrier function could treat ischemic stroke. In mice with middle cerebral artery occlusion-induced stroke, endothelial cell-specific knockout of the miR-15a/miR-16-1 cluster reduced infarct...
BC Innovations | May 17, 2018

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BC Innovations | Aug 17, 2017
Targets & Mechanisms


Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
BC Innovations | Aug 16, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Self-assembling multicellular BBB spheroids could help screen compounds for BBB permeability. The spheroids self-assembled from co-cultures of primary human astrocytes, brain vascular pericytes and either brain microvascular endothelial cells or a human...
BC Innovations | Jul 26, 2017
Emerging Company Profile

Breaching the gates

Junction Therapeutics Ltd. ’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of...
BC Innovations | Oct 8, 2015
Translation in Brief

Holey BBB

A study from Trinity College Dublin has shown that reducing the levels of two tight junction proteins can loosen the blood-brain barrier and let soluble β-amyloid monomers slip out of the brain through the spaces...
BC Innovations | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Claudin 5 (CLDN5); occludin (OCLN); β amyloid (Aβ)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting CLDN5 and OCLN could help treat AD. In endothelial cell cultures, knockdown of both CLDN5 and OCLN increased paracellular diffusion of Aβ monomers...
BC Innovations | May 31, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Claudin 5 (CLDN5) Mouse studies suggest blocking CLDN5 in the brain could help relieve brain edema and help treat traumatic brain injury. In mice,...
BC Innovations | Oct 29, 2009
Cover Story

Breaching the retinal barrier

Trinity College Dublin researchers have developed a way to use RNAi to reversibly enhance the permeability of the blood retina barrier. 1 The technique improved systemic delivery of two small molecules to the mouse retina,...
BC Innovations | Feb 5, 2009
Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Inflammation Inflammation VEGFA; claudin 5 (CLDN5) Studies in cell culture and in mice suggest that upregulating CLDN5 could be useful...
Items per page:
1 - 10 of 10